Semax vs Selank Compared

Semax and Selank are almost always discussed together, and almost always inaccurately. They share an origin, a country of development and a structural design principle — and beyond that they are studied in largely separate literatures. What follows separates what is documented from what is repeated.

Proxiva Catalogue DeskFormats, presentations and per-milligram economics

The problem with most of what is written about these two

Before the comparison itself, a caveat that materially affects how much weight any of it deserves.

Both compounds were developed in Russia, and a substantial portion of the primary research on them was published in Russian-language journals, some of it decades ago. English-language secondary sources describing these peptides frequently cite each other rather than the underlying work, and the chain of citation is often several links long before it reaches anything primary.

The practical effect is that specific claims circulate with far more confidence than the underlying evidence supports. Where a description of either compound sounds unusually precise about outcomes, it is worth asking what it is actually citing.

What follows is restricted to what is structurally and mechanistically documented, which is a narrower set of claims than most write-ups make.

Shared design, different parents

Both compounds are built on the same engineering idea. Take a short fragment of a naturally occurring peptide that has some activity of interest, then attach a stabilising sequence so the fragment survives long enough to be useful. Native peptide fragments are typically degraded very rapidly by peptidases; the tail slows that.

In both cases the tail is Pro-Gly-Pro — proline, glycine, proline. This is the feature that makes the two compounds look related in structural diagrams, and it is the source of most of the confusion about them.

The fragments the tail is attached to are not related at all:

ACTH and tuftsin are unrelated molecules with unrelated functions. Describing Semax and Selank as variants of one another is roughly as accurate as describing two unrelated proteins as similar because both were expressed in the same cell line.

What the Semax literature examines

Semax is derived from the ACTH(4-10) fragment. The parent hormone's endocrine function is not what the fragment was selected for — the fragment was chosen because it retains activity in the nervous system without the hormonal effects of the full molecule.

The research is predominantly neurological. Where mechanism is discussed, neurotrophic factor expression is the most commonly examined route, with brain-derived neurotrophic factor appearing frequently in the literature.

It is available in research catalogues as Semax 10mg and combined with its counterpart as the Selank and Semax blend.

What the Selank literature examines

Selank descends from tuftsin, a short peptide with a documented role in immune modulation — specifically in stimulating phagocytic activity. That origin sets a different research context from the outset.

The published work on Selank divides between immunological and neurological framings, with the anxiolytic literature examining GABAergic involvement and, in some work, monoamine systems. The dual character reflects the parent molecule: an immune peptide with reported central effects.

Listed as Selank 10mg, and in blend form alongside Semax.

Researchers examining this general area frequently also stock unrelated nootropic-context compounds such as DSIP or 5-Amino-1MQ for comparison across mechanisms.

Why the blend exists

Because the two are studied in adjacent but non-overlapping contexts, protocols examining both are common, and a pre-combined vial removes one reconstitution step.

The trade is the usual one. A blend fixes the ratio at whatever the manufacturer selected; separate vials of Semax and Selank leave that ratio under your control. If the ratio is a variable in the work, buy them separately. If it is fixed anyway, the blend removes a handling step and a source of error.

Both are also encountered in nasal-spray formats in some catalogues, which introduces a separate set of stability considerations, since a spray is a solution rather than a lyophilised powder.

Verification and handling

Nothing about either compound requires unusual handling. Both are short peptides and follow standard practice — lyophilised powder cold and dark, reconstitution with bacteriostatic water for multi-draw vials, refrigeration afterwards, no re-freezing.

On verification, the shared Pro-Gly-Pro tail is a reason to weight the mass-spectrometry result carefully. The two compounds have different molecular weights, but their structural similarity means a purity trace alone is not a strong identity signal. Confirm the mass matches the theoretical value for the compound named.

Beyond that the standard checks apply: batch number matching the vial, purity at 98% or above, chromatogram image present, testing laboratory named, residual solvent panel included. Our guide to reading a certificate of analysis covers each field, and storage and stability covers what happens after arrival.

Reading claims about either compound

Given the citation problem described above, a practical filter is useful for evaluating any specific claim encountered about these two.

Ask what is being cited. A claim traced through three English-language blogs to a Russian abstract from the 1990s is not thereby false, but it is considerably weaker than a claim citing a primary study directly. Where sources cite only each other, the chain has no anchor.

Distinguish mechanism from outcome. That Semax derives from ACTH(4-10) and carries a Pro-Gly-Pro tail is a structural fact, verifiable from the sequence. That it produces a specific effect is a different order of claim requiring different evidence. Structural claims about these compounds are well supported; outcome claims frequently are not.

Notice unusual precision. Descriptions carrying specific figures about magnitude or duration are making quantitative claims, which require quantitative studies. Where the underlying literature is sparse, precision is a warning rather than a reassurance.

Separate the two compounds. Because they are so often discussed together, claims about one migrate to the other. A source treating them as interchangeable has already made an error that undermines whatever follows.

Applied consistently, this filter removes most of what circulates about both peptides and leaves a smaller, better-supported core — which is the appropriate basis for research decisions.

What is documented, in summary

Reducing both compounds to claims that rest on structure rather than interpretation:

• Both are synthetic peptides of Russian origin, built by attaching a Pro-Gly-Pro tail to a fragment of a native peptide.
• Semax derives from ACTH(4-10). Selank derives from a tuftsin analogue. The parent molecules are unrelated.
• The tail extends resistance to enzymatic degradation, which is the reason the fragments are usable at all.
• Semax appears predominantly in neurotrophic and cognitive research contexts; Selank predominantly in anxiolytic and immunomodulatory ones.
• Both are short peptides requiring no unusual handling.

Everything beyond that list — magnitudes, durations, comparative potency, specific outcomes — depends on literature that is genuinely difficult to evaluate from English-language sources, and should be treated as less settled than its confident restatement online suggests.

For sourcing, both are available as Semax and Selank individually or as a combined vial, and the verification requirements are identical to any other research peptide.

Frequently asked questions

Research use only. All products referenced on this page are sold strictly for laboratory and research purposes. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. Handling should be performed only by qualified individuals in an appropriate laboratory setting.